BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
QuintilesIMS
US Department of Justice
Covington
Fuji
Merck
Healthtrust
Farmers Insurance
Federal Trade Commission
Queensland Health

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091680

« Back to Dashboard

NDA 091680 describes DIETHYLPROPION HYDROCHLORIDE, which is a drug marketed by Lannett Holdings Inc, Avanthi Inc, Chartwell Rx, Epic Pharma Llc, Sandoz, Teva, Ucb Inc, and Watson Labs, and is included in ten NDAs. It is available from eleven suppliers. Additional details are available on the DIETHYLPROPION HYDROCHLORIDE profile page.

The generic ingredient in DIETHYLPROPION HYDROCHLORIDE is diethylpropion hydrochloride. There are eleven drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the diethylpropion hydrochloride profile page.
Summary for 091680
Tradename:DIETHYLPROPION HYDROCHLORIDE
Applicant:Lannett Holdings Inc
Ingredient:diethylpropion hydrochloride
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 091680
Medical Subject Heading (MeSH) Categories for 091680
Suppliers and Packaging for NDA: 091680
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DIETHYLPROPION HYDROCHLORIDE diethylpropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 091680 ANDA Lannett Company, Inc. 0527-1477 0527-1477-25 250 TABLET, EXTENDED RELEASE in 1 BOTTLE (0527-1477-25)
DIETHYLPROPION HYDROCHLORIDE diethylpropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 091680 ANDA Lannett Company, Inc. 0527-1477 0527-1477-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0527-1477-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength75MG
Approval Date:Oct 24, 2011TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Citi
Medtronic
Novartis
Queensland Health
US Department of Justice
UBS
Farmers Insurance
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot